logo

Metabolomics InveStigation of cyStic fIbrosis pulmOnary exacerbatioNs

Sector: Chemical (Industrial) • Location: France

Source: EU Funding & Tenders Portal

Project
Ended

Cystic fibrosis (CF) is a lethal genetic disease affecting 1 out of 2500 newborns. In CF patients, compromised innate immunity enhances the susceptibility to colonization of lower airways by different microbes, leading to long-term bacterial infections. Data suggests that the resulting host-pathogen interactions can shape the course of disease progression, but this relationship is still poorly und

Project Information FAQ

Project Information

4 Q
The project “Metabolomics InveStigation of cyStic fIbrosis pulmOnary exacerbatioNs” is an infrastructure initiative in the Chemical (Industrial) sector, located in France. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

Cystic fibrosis (CF) is a lethal genetic disease affecting 1 out of 2500 newborns. In CF patients, compromised innate immunity enhances the susceptibility to colonization of lower airways by different microbes, leading to long-term bacterial infections. Data suggests that the resulting host-pathogen interactions can shape the course of disease progression, but this relationship is still poorly understood. I propose to use CF patients' samples of exhaled breath condensate to investigate intra-microbial interactions and host-responses, especially during pulmonary exacerbations (PEx), which are recurrent episodes of acute worsening of respiratory symptoms, adversely influencing patients' quality of life. Metabolomics (i.e., the exploration of small molecules within a biological system under defined conditions) has been acknowledged to be the omics discipline closest to the actual phenotype. Thus, I plan to use an unbiased metabolomics approach based on liquid chromatography-mass spectrometry to investigate the chemical environment of CF lungs, with the aim of reducing interpatient variability, characteristic of CF, to increase the generalisability of the findings. I will combine this approach with clinical information and cell biology techniques to test the immune response modulation in vitro, and shed light on the important roles played by metabolites present in CF airways in the regulation of host immune responses. Targeting the main hurdles in finding a cure for CF patients, namely the interpatient variability and the elucidation of the immunopathogenesis of CF, the expected results will give a necessary contribution to the understanding of CF mechanisms, that are still largely unknown. This knowledge is in turn fundamental to guide personalised clinical decisions for early intervention and amelioration of PEx treatment. To the best of our knowledge, there are not yet studies proposing a similar methodology to achieve such an ambitious goal.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data